Last reviewed · How we verify

Lidocaine 1%/Epi 1:200000

Wahba bakhet · FDA-approved active Small molecule

Lidocaine 1%/Epi 1:200000 is a Local anesthetic with vasoconstrictor Small molecule drug developed by Wahba bakhet. It is currently FDA-approved for Local anesthesia for infiltration, nerve blocks, and topical procedures, Dental anesthesia, Minor surgical procedures requiring local anesthesia. Also known as: Xylocaine 1%/Epi 1:200000.

Lidocaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption.

Lidocaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption. Used for Local anesthesia for infiltration, nerve blocks, and topical procedures, Dental anesthesia, Minor surgical procedures requiring local anesthesia.

At a glance

Generic nameLidocaine 1%/Epi 1:200000
Also known asXylocaine 1%/Epi 1:200000
SponsorWahba bakhet
Drug classLocal anesthetic with vasoconstrictor
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that reversibly inhibits sodium influx into nerve fibers, preventing depolarization and action potential propagation. The addition of epinephrine (1:200,000 concentration) acts as a vasconstrictor on local blood vessels, which slows the systemic absorption of lidocaine, extends its duration of action at the injection site, and reduces the risk of systemic toxicity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lidocaine 1%/Epi 1:200000

What is Lidocaine 1%/Epi 1:200000?

Lidocaine 1%/Epi 1:200000 is a Local anesthetic with vasoconstrictor drug developed by Wahba bakhet, indicated for Local anesthesia for infiltration, nerve blocks, and topical procedures, Dental anesthesia, Minor surgical procedures requiring local anesthesia.

How does Lidocaine 1%/Epi 1:200000 work?

Lidocaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption.

What is Lidocaine 1%/Epi 1:200000 used for?

Lidocaine 1%/Epi 1:200000 is indicated for Local anesthesia for infiltration, nerve blocks, and topical procedures, Dental anesthesia, Minor surgical procedures requiring local anesthesia.

Who makes Lidocaine 1%/Epi 1:200000?

Lidocaine 1%/Epi 1:200000 is developed and marketed by Wahba bakhet (see full Wahba bakhet pipeline at /company/wahba-bakhet).

Is Lidocaine 1%/Epi 1:200000 also known as anything else?

Lidocaine 1%/Epi 1:200000 is also known as Xylocaine 1%/Epi 1:200000.

What drug class is Lidocaine 1%/Epi 1:200000 in?

Lidocaine 1%/Epi 1:200000 belongs to the Local anesthetic with vasoconstrictor class. See all Local anesthetic with vasoconstrictor drugs at /class/local-anesthetic-with-vasoconstrictor.

What development phase is Lidocaine 1%/Epi 1:200000 in?

Lidocaine 1%/Epi 1:200000 is FDA-approved (marketed).

What are the side effects of Lidocaine 1%/Epi 1:200000?

Common side effects of Lidocaine 1%/Epi 1:200000 include Injection site pain or burning, Transient paresthesia, Allergic reaction (rare with amide lidocaine), Systemic toxicity (CNS or cardiac effects at high doses), Headache.

What does Lidocaine 1%/Epi 1:200000 target?

Lidocaine 1%/Epi 1:200000 targets Voltage-gated sodium channels and is a Local anesthetic with vasoconstrictor.

Related